Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were down 14.5% on Monday . The company traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares changed hands during mid-day trading, a decline of 36% from the average daily volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The stock has a market capitalization of C$23.09 million, a price-to-earnings ratio of -13.25 and a beta of 0.20. The company has a 50-day moving average of C$0.11 and a 200-day moving average of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How to Invest in Blue Chip Stocks
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Market Cap Calculator: How to Calculate Market Cap
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
